Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over yearBranded revenue of $83.5 million, up 62% year over year and approximately 84% of
PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx,
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and
NASHVILLE, Tenn., Oct. 26, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
NASHVILLE, Tenn., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has closed its previously announced
NASHVILLE, Tenn., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that 15 scientific abstracts featuring data
NASHVILLE, Tenn., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the
NASHVILLE, Tenn., Aug. 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced positive results from a prospective,
Second Quarter 2026 and Selected Highlights: Quarterly revenue of $70.7 million, an increase of 60% sequentially, and 11% year over yearReiterated full-year 2026 financial guidance of $350 million to $365 million in
NASHVILLE, Tenn., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has entered into a definitive agreement
NASHVILLE, Tenn., July 27, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for
A real-world PMS study based on a large population demonstrates comparable safety profile of SB11 (BYOOVIZ® / AMELIVU®) to reference ranibizumabIn treatment-naïve patients, SB11 provided functional and anatomical
NASHVILLE, Tenn., July 20, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the presentation of three studies supporting
NASHVILLE, Tenn., July 01, 2026 (GLOBE NEWSWIRE) -- Harrow (NASDAQ:HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the commercial launch of BYOOVIZ®
In July 2025, Samsung Bioepis entered into partnership with Harrow for commercialization of two interchangeable ophthalmology biosimilars — BYOOVIZ® (ranibizumab-nuna) and OPUVIZ™ (aflibercept-yszy) — in the
